• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams Imidolactams
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams

Recent Advances in the Study of 5-(Methoxymethyl)-1H-pyrazol-3-amine (CAS: 739366-03-1) in Chemical Biology and Pharmaceutical Research

The compound 5-(methoxymethyl)-1H-pyrazol-3-amine (CAS: 739366-03-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic amine, characterized by a pyrazole core with a methoxymethyl substituent, has demonstrated promising biological activities, making it a valuable scaffold for the synthesis of novel therapeutic agents. Recent studies have explored its potential as a key intermediate in the synthesis of kinase inhibitors, anti-inflammatory agents, and antimicrobial compounds, highlighting its broad utility in medicinal chemistry.

One of the most notable advancements in the study of 5-(methoxymethyl)-1H-pyrazol-3-amine is its role in the development of kinase inhibitors. Kinases are critical targets in the treatment of various cancers and inflammatory diseases, and the pyrazole moiety of this compound has been shown to effectively interact with the ATP-binding sites of several kinases. Recent publications have detailed the synthesis of derivatives of 5-(methoxymethyl)-1H-pyrazol-3-amine that exhibit potent inhibitory activity against specific kinases, such as JAK2 and EGFR, which are implicated in myeloproliferative disorders and non-small cell lung cancer, respectively. These findings underscore the compound's potential as a scaffold for designing next-generation kinase inhibitors with improved selectivity and efficacy.

In addition to its applications in kinase inhibition, 5-(methoxymethyl)-1H-pyrazol-3-amine has also been investigated for its anti-inflammatory properties. A recent study demonstrated that derivatives of this compound can modulate the activity of key inflammatory mediators, such as NF-κB and COX-2, thereby reducing inflammation in preclinical models. The methoxymethyl group was found to enhance the bioavailability and metabolic stability of these derivatives, making them attractive candidates for further development as anti-inflammatory drugs. These results suggest that 5-(methoxymethyl)-1H-pyrazol-3-amine could serve as a foundation for novel therapies targeting chronic inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the antimicrobial potential of 5-(methoxymethyl)-1H-pyrazol-3-amine. Researchers have synthesized a series of analogs incorporating this scaffold and evaluated their activity against a panel of bacterial and fungal pathogens. Preliminary data indicate that certain derivatives exhibit broad-spectrum antimicrobial activity, with minimal cytotoxicity to mammalian cells. The mechanism of action appears to involve disruption of microbial cell wall synthesis and inhibition of essential enzymes, such as dihydrofolate reductase. These findings highlight the compound's potential as a lead structure for developing new antimicrobial agents, particularly in the face of rising antibiotic resistance.

Despite these promising developments, challenges remain in the optimization of 5-(methoxymethyl)-1H-pyrazol-3-amine-based compounds for clinical use. Issues such as solubility, pharmacokinetics, and off-target effects need to be addressed through further structural modifications and in vivo studies. However, the versatility and biological activity of this scaffold make it a compelling subject for ongoing research. Future studies are expected to explore its applications in other therapeutic areas, such as neurodegenerative diseases and metabolic disorders, further expanding its impact on drug discovery.

In conclusion, 5-(methoxymethyl)-1H-pyrazol-3-amine (CAS: 739366-03-1) represents a highly promising scaffold in chemical biology and pharmaceutical research. Its applications in kinase inhibition, anti-inflammatory therapy, and antimicrobial drug development underscore its versatility and potential for addressing unmet medical needs. Continued research into its derivatives and mechanisms of action will likely yield innovative therapeutic candidates, solidifying its role in the advancement of modern medicine.

• 1228351-41-4(Methyl 3-Amino-1H-pyrazole-5-carboxylate hydrochloride)
• 1312929-42-2(Methyl 5-amino-1H-pyrazole-3-carboxylate)
• 1000895-26-0((3-Amino-1H-pyrazol-5-yl)methanol)
• 1254966-70-5(Methyl 3-Amino-1H-pyrazole-5-carboxylate hydrochloride)
• 948571-48-0((3-Amino-1H-pyrazol-5-yl)methanol)
• 393590-62-0(5-((Benzyloxy)methyl)-1H-pyrazol-3-amine)
• 632365-54-9(methyl 3-amino-1H-pyrazole-5-carboxylate)
• 1185908-13-7(3-(benzyloxymethyl)-1H-pyrazol-5-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)